Literature DB >> 11902574

Histone deacetylases and cancer: causes and therapies.

P Marks1, R A Rifkind, V M Richon, R Breslow, T Miller, W K Kelly.   

Abstract

Together, histone acetyltransferases and histone deacetylases (HDACs) determine the acetylation status of histones. This acetylation affects the regulation of gene expression, and inhibitors of HDACs have been found to cause growth arrest, differentiation and/or apoptosis of many tumours cells by altering the transcription of a small number of genes. HDAC inhibitors are proving to be an exciting therapeutic approach to cancer, but how do they exert this effect?

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11902574     DOI: 10.1038/35106079

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  543 in total

1.  A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.

Authors:  Tapan M Kadia; Hui Yang; Alessandra Ferrajoli; Sirisha Maddipotti; Claudia Schroeder; Timothy L Madden; Julianne L Holleran; Merrill J Egorin; Farhad Ravandi; Deborah A Thomas; Willie Newsome; Blanca Sanchez-Gonzalez; James A Zwiebel; Igor Espinoza-Delgado; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Br J Haematol       Date:  2010-04-29       Impact factor: 6.998

2.  Regulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancer.

Authors:  Qi Shen; Wanfen Tang; Jie Sun; Lifeng Feng; Hongchuan Jin; Xian Wang
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

3.  The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells.

Authors:  Ke Long Jin; Jeong-Yeol Park; Eun Joo Noh; Kwang Lae Hoe; Joo Hak Lee; Jong-Hyeok Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

Review 4.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 5.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

6.  Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

Authors:  Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin Ryan; Ivana Gojo; Jurgen Venitz; William D Figg; Alex Sparreboom
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

7.  BIX01294 suppresses osteoclast differentiation on mouse macrophage-like Raw264.7 cells.

Authors:  Hiromasa Tsuda; Ning Zhao; Kenichi Imai; Kuniyasu Ochiai; Pishan Yang; Naoto Suzuki
Journal:  Bosn J Basic Med Sci       Date:  2013-11       Impact factor: 3.363

Review 8.  Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.

Authors:  Jürgen Sonnemann; Jennifer Gänge; K Saravana Kumar; Cornelia Müller; Peter Bader; James F Beck
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

Review 9.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

10.  Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.

Authors:  Durgadevi Ravillah; Altaf Mohammed; Li Qian; Misty Brewer; Yuting Zhang; Laura Biddick; Vernon E Steele; Chinthalapally V Rao
Journal:  J Pharmacol Exp Ther       Date:  2013-11-11       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.